MaxCyte reported a 49% increase in total revenue to $10.2 million for Q3 2026, driven by 27% growth in core business revenue and higher SPL program-related income. The company raised its full-year 2026 revenue guidance to at least $34.5 million, reflecting strong momentum and growth in cell therapy programs. MaxCyte also announced its proposed acquisition of Akron Bio, which will expand its offerings in cell therapy manufacturing and nearly double its revenue base. This strategic move is expected to enhance MaxCyte's commercial opportunities and financial profile going forward.
MaxCyte's Q3 2026 revenue rose 49% to $10.2 million, with the company raising its full-year revenue guidance to at least $34.5 million. For readers following the health sector, here is Pluang's market snapshot as of Nov 10, 2026 17:11 WIB: out of 150 priced US health stocks, 70 rose and 65 fell. Notable movers include BBIO at USD 76.71 with a 1-day change of -1.57% and a typical hold time on Pluang of 65 days, LFST at USD 14.81 up 1.44%, and ENVB at USD 1.46 up 1.39%.
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
The global paracetamol market is projected to grow from $12.05 billion in 2026 to $15.39 billion by 2032, with a CAGR of 4.12%. Growth is driven by increasing demand for pain and fever management, expanded access to over-the-counter medicines, and in...
ESET Research uncovered a sophisticated cyberespionage tool named Cereal, used by the Russia-aligned Turla group to spy on emails within Microsoft Exchange servers of governmental organizations in Kazakhstan and Romania. The tool stealthily collects ...
Registration is now open for Brand Licensing Expo 2027, scheduled for May 25-27 at Mandalay Bay, Las Vegas. The event, rebranded from Licensing Expo, features over 265 confirmed exhibitors including major brands like Amazon MGM Studios, Coca-Cola, an...
Wix reported Q3 2026 earnings per share of $1.42, surpassing the $1.40 estimate, and revenue of $570.2 million, exceeding the $566.3 million forecast. Bookings grew 11% to $573 million, with revenue up 13%, driven mainly by Base44's strong performanc...
